Epinephrine Injection 8 mg per 250 mL in 0.9% Sodium Chloride, 8mg, 250 mL excel bag, Rx only, Athenex Pharma Solutions, LLC, Clarence, NY, 14031, NDC 76154-814-15
Athenex Pharma Solutions
Defective container
💊 Drugs • 11,927 recalls
Athenex Pharma Solutions
Defective container
cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.
cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.
Athenex Pharma Solutions
Defective container
Teligent Pharma
cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.
cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.
cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.
Olympia Compounding Pharmacy
Sub Potent
Athenex Pharma Solutions
Defective container
cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.
cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.
cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.
cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.
cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.
Olympia Compounding Pharmacy
Sub Potent
Athenex Pharma Solutions
Defective container
Athenex Pharma Solutions
Defective container
cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.
Athenex Pharma Solutions
Defective container
cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.